Kentucky 2025 Regular Session

Kentucky House Bill HB685

Introduced
2/18/25  
Refer
2/18/25  

Caption

AN ACT relating to the 340B Drug Pricing Program.

Impact

If enacted, HB 685 would significantly alter the accountability requirements for nonprofit hospitals, mandating the submission of detailed reports on program operations and financial implications. This increased scrutiny is expected to benefit both state health oversight and the financial ecosystem of healthcare service provision, ensuring that profits derived from the program are passed on to patients in the form of lower costs or charity services. Moreover, the provision for a sliding fee scale for low-income patients is designed to improve access to essential medications for some of the state's most vulnerable populations.

Summary

House Bill 685 aims to regulate the operations of nonprofit hospitals in relation to the 340B Drug Pricing Program, which is a federal initiative allowing these hospitals to purchase outpatient drugs at discounted prices. The bill requires nonprofit hospitals to report specific data concerning their acquisition and distribution of 340B drugs to the Kentucky Cabinet for Health and Family Services annually. This includes detailed information on costs, earnings from the program, and patient access provisions associated with the drugs dispensed under the program. The legislation seeks to enhance transparency and ensure that the benefits of the Drug Pricing Program effectively serve low-income patients.

Sentiment

Sentiment surrounding HB 685 appears mostly supportive among healthcare advocacy groups and legislators focused on public health, as it creates a pathway toward ensuring that the 340B program benefits those most in need. However, there may be concerns from the hospital sector regarding the administrative burden and compliance costs associated with more stringent reporting requirements. The overall sentiment reflects a commitment to enhancing healthcare accessibility while balancing the operational realities that nonprofit hospitals face.

Contention

Some notable points of contention may arise regarding the implications of increased oversight on nonprofit hospitals. Critics of the bill might argue that excessive regulation could limit the hospitals' ability to operate effectively, diverting resources towards compliance rather than patient care. Furthermore, the balance between ensuring that savings reach patients rather than being absorbed by administrative costs remains an area of debate. As hospitals prepare to adapt to the changes mandated by this legislation, concerns about their capacity to maintain service levels while complying with new reporting requirements could emerge.

Companion Bills

No companion bills found.

Similar Bills

KY SB153

AN ACT relating to prepayment review of Medicaid claims.

KY SB14

AN ACT relating to pharmaceutical manufacturers.

VA HB2375

Prescription drug price transparency; pharmacy services administrative organizations.

VA HB2392

Health insurance; pharmacy benefits managers, definition of "covered entity."

VA SB1311

Health insurance; pharmacy benefits managers, definition of "covered entity."

TX SB1564

Relating to pharmacy benefit networks and pharmacy benefit managers.

TX HB1881

Relating to pharmacy benefit networks and pharmacy benefit managers.

MD HB321

Pharmacy Benefits Managers – Definition of Purchaser and Alteration of Application of Law